Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on the day's biggest business stories

Subscribe to Axios Closer for insights into the day’s business news and trends and why they matter

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Stay on top of the latest market trends

Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Illustration: Sarah Grillo/Axios

In the race to create a vaccine for the novel coronavirus, some researchers are testing new approaches they hope can ultimately produce vaccines in months rather than years.

Why it matters: The global COVID-19 outbreak is a harsh reminder of the urgent need to be able to vaccinate large swaths of the population fast — in this pandemic and the next.

What's happening: The world is pinning its hopes on a vaccine for COVID-19 to save lives, return to normal and emerge from an economic recession.

  • Experts estimate it could take at least 12–18 months for a vaccine to be widely available, with glimmers of hope for some limited availability sooner tempered by a reality that vaccines typically take multiple years to develop.

The state of play: There are at least 92 vaccines under development for COVID-19.

  • 22 of those are experimental DNA- or RNA-based vaccines, which provide the most hope for speedy development.
  • "These technologies will be pushed to limits they’ve never been pushed to before and we’ll see how they perform," says Harvard Medical School's Dan Barouch of DNA and RNA vaccines. "We’ll know a lot more about the status of these technologies at the end of COVID-19."

Background: For more than 200 years, vaccines have worked by introducing the body to either a version of the virus itself that doesn't cause disease, or an antigen that's typically a protein on the virus surface. Both prime the immune system and spur it into action should someone encounter the virus.

  • Those approaches gave the world effective vaccines for polio, measles, hepatitis B and other diseases.
  • But each time, researchers have to develop anew the biological machinery — cells and reactor conditions — needed to manufacture the vaccines.
  • "It is a unique problem for every vaccine you make," says Fred Hutch's Andy McGuire who works on the design of HIV vaccines.
  • But, this simply takes too much time during times of crisis, per Johns Hopkins Center for Health Security's Amesh Adalja.

What's new: DNA and RNA vaccines are a potential avenue for speeding up vaccine development.

  • Instead of delivering the antigen, these vaccines introduce the DNA or RNA sequence that encodes the antigen and it is produced by the body's cells. (RNA acts as an information-carrying intermediary between DNA and the protein it encodes.)
  • When a new virus emerges, the idea is an antigen from it could be quickly sequenced and the genetic code plugged into an already-approved vaccine platform with an existing tried-and-true manufacturing process. That would eliminate the long process of developing a line of cells for producing the vaccine.

But, but, but: No RNA and DNA vaccines have been approved for humans — for any virus.

  • DNA vaccines, which have been in development for two decades, sometimes struggle to cause a strong immune response to a virus.
  • RNA vaccines are a newer approach, and delivering them to the right cells can be a challenge.
  • Vaccines for hepatitis C, malaria and other viral diseases are being developed with the platform. Biotechnology company Moderna created a RNA vaccine for Zika during the outbreak in 2015. But the virus largely went away and the vaccine wasn't tested in an outbreak.

Several teams are working on RNA vaccines for SARS-CoV-2, the virus that causes COVID-19, including Moderna and the NIH's Vaccine Research Center. Their RNA vaccine is in Phase I trials in three sites, testing the safety of doses and whether it can induce an immune response in humans.

  • "If it works, it is a good technology to respond quickly. It has not been shown to work in terms of protection and to be mass produced, " Barouch says. "It doesn’t mean they can’t be, they just haven’t yet."

Meanwhile, Barouch and his collaborators at Johnson & Johnson are taking a different approach, using a non-infectious version of an adenovirus — a common cold virus— to shuttle DNA for an antigen into the body's cells.

  • The experimental platform was developed for an Ebola vaccine and Barouch says, unlike RNA and DNA vaccines, it is grown in cells and has a proven ability to scale up.
  • J&J committed to producing 1 billion vaccines worldwide, if it's successful.

The big picture: Testing vaccines quickly and not relying on cells to manufacture them would be a game changer for future pandemics.

  • "It sets the stage for being able to respond quickly to a variety of pandemics that could emerge by having capabilities for manufacturing without having to go through cell line development," says Northwestern University's Mike Jewett, a biochemical engineer who is developing systems for manufacturing vaccines and drugs without cells.
  • Moving vaccine production out of cells could be one component for decentralized, local production of medicine, vaccines and diagnostics for responding to pandemics and addressing antibiotic resistant microbes, he says.

The bottom line: This pandemic is a testbed for the next generation of vaccine technologies.

Go deeper:

Go deeper

Updated Dec 8, 2020 - Health

The states where face coverings are mandatory

Data: Compiled by Axios; Map: Danielle Alberti/Axios

Wyoming on Monday became the latest state to implement a mask mandate to fight COVID-19, amid a steep spike in cases across the country.

The big picture: States are reintroducing mitigation efforts like closing businesses and advising people to stay home as the U.S. averages the most daily cases of any point in the pandemic.

Updated Oct 7, 2020 - Health

World coronavirus updates

Expand chart
Data: The Center for Systems Science and Engineering at Johns Hopkins; Map: Axios Visuals

New Zealand now has active no coronavirus cases in the community after the final six people linked to the Auckland cluster recovered, the country's Health Ministry confirmed in an email Wednesday.

The big picture: The country's second outbreak won't officially be declared closed until there have been "no new cases for two incubation periods," the ministry said. Auckland will join the rest of NZ in enjoying no domestic restrictions from late Wednesday, Prime Minister Jacinda Ardern said, declaring that NZ had "beat the virus again."

Updated 13 hours ago - Politics & Policy

Coronavirus dashboard

Illustration: Annelise Capossela/Axios